An interventional study of myoma removal in Myoma and Hypertension, sponsored by Shiraz University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to female participants aged 22 Years to 55 Years. Per ClinicalTrials.gov, last updated 2009-05-12.
Sponsored by Shiraz University of Medical Sciences · Not applicable, Interventional, and Diagnostic
The effect of myoma removal was studied on 28 patients with hypertension and myoma by holter monitoring and erythropoetin level check.
Background:
Myoma is the most common gynecoid tumor and produces many vasoactive substances, which may be a cause for secondary hypertension. Early reports suggested the association of myoma and hypertension. We studied the effect of myoma removal on hypertension and erythropoietin level to evaluate this hypothesis.
Patients \& Methods:
In this single centered prospective cohort study, in twenty eight patients who were candidates for myomectomy due to myoma, 24 hour holter monitoring of blood pressure and serum erythropoietin were checked before and 6 weeks after hysterectomy.
61 studies on the registry are indexed under Myoma; 10 are open to participants now.
This study's enrollment of 28 is below the median of 80 across 45 interventional studies indexed under Myoma.
Browse Myoma studies →Shiraz University of Medical Sciences is the lead sponsor of 130 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
those with myoma with or without hypertension in holter monitoring
Procedure: myoma removal
surgical removal of myoma by hysterectomy
24 hour holter monitoring of blood pressure
Time frame: 6 weeks
erythropoetin level
Time frame: 6 weeks
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shiraz University of Medical Sciences →